A vision for the National Cancer Program in the United States

Nature Reviews Cancer

Volumn 4, Issue 10, 2004, Pages 820-828

  Von Eschenbach, Andrew C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; DASATINIB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR; GEFITINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBRITUMOMAB TIUXETAN; IMATINIB; ISOFLAVONE DERIVATIVE; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYPHENOL DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAF PROTEIN; TAMOXIFEN; TOSITUMOMAB; TUMOR MARKER; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALGORITHM; BIOINFORMATICS; BREAST CANCER; CANCER GENETICS; CANCER MODEL; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC IMAGING; DNA MICROARRAY; DRUG EFFICACY; DRUG TARGETING; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GENETIC EPIDEMIOLOGY; HEALTH CARE ORGANIZATION; HUMAN; LAW; LUNG NON SMALL CELL CANCER; MEDICAL TECHNOLOGY; MOLECULAR BIOLOGY; MOTIVATION; MULTIPLE MYELOMA; NANOTECHNOLOGY; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UNITED STATES; UTERINE CERVIX CANCER;

ANIMALS; BIOTECHNOLOGY; CANCER CARE FACILITIES; CHEMOPREVENTION; CLINICAL TRIALS; COMPUTATIONAL BIOLOGY; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; GOALS; HUMANS; MICE; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; PROTEOMICS; RESEARCH; UNITED STATES;

EID: 4944242884     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1458     Document Type: Review

References (37)

1. Leaf, C. Why we're losing the war on cancer (and how to win it). Fortune 149, 76-97 (2004).
2. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
3. Kitano, H. Cancer robustness: tumour tactics. Nature 426, 125-125 (2003).
4. Pantschenko, A. G. et al. The interteukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Intl. J. Oncol. 23, 269-284 (2003).
5. Ideker, T. et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292, 929-933 (2001).
6. Site, G. A. Introduction to nanotechnology and its applications to medicine. Surg. Oncol. 61, 216-220 (2004).
7. Etzioni, R. et al. The case for early detection. Nature Rev. Cancer 3, 2-10 (2003).
8. Conrads, T. P. et al. High-resolution serum proteomic features for ovarian cancer detection. Endocr. Relat. Cancer 11, 163-187 (2004).
9. Petricoin, E. F. et al. Serum proteomic patterns for detection of prostate cancer. Brief Communications. J. Natl Cancer Inst. 94, 1576-1578 (2002).
10. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
11. National Cancer Institute. NCI and FDA Announce Joint Program to Streamline Cancer Drug Development [online], 〈http://www.cancer.gov/ newscenter/pressreleases/NciFdaCollab〉 (2003).
12. Staudt, L. M. Molecular diagnosis of the hematologic cancers. N. Engl. J. Med. 348, 1777-1785 (2003).
13. Druker, B. J., O'Brien, S. G., Cortes, J. & Radich, J. Chronic myelogenous leukemia. Hematology 1, 111-135 (2002).
14. Druker, B. J. Perspective on the development of a molecularly targeted agent. Cancer Cell 1, 31-36 (2002).
15. Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401 (2004).
16. Logrono, R., Jones, D. V., Faruqi, S. & Bhutani, M. S. Recent advances in cell biology, diagnosis and therapy of gastrointestinal stromal tumor (GIST). Cancer Biol. Ther. 3, 251-258 (2004).
17. Paez, J. G. et al. EGFR mutation in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
18. National Cancer Institute. NCI Awards $42 Million to Fund New Cancer Prevention Clinical Trials Consortium to Study Promising New Agents [online], 〈http://www.cancer.gov/newscenter/pressreleases/prev enttrials〉 (2003).
19. Koutsky, L. A. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651 (2002).
20. Gross, P. E. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793-1802 (2003).
21. Hawk, E. T. et al. Cancer and the cyclooxygenase enzymes: implications for the treatment and prevention of cancer. Am. J. Cancer 2, 27-55 (2003).
22. Steinbach, G. et al. The effect of celecoxib, a cycloxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946-1952 (2000).
23. Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and economic costs - United States, 1995-1999. MMWR Morb. Mortal. Wkly Rep. 51, 300-303 (2002).
24. Centers for Disease Control and Prevention. Cigarette Smoking Among Adults - United Stated, 2002. MMWR Morb. Mortal. Wkly Rep. 53, 427-431 (2004).
25. Murray, C. J. & Lopez, A. D. (eds) The Global Burden of Disease 183 (Harvard Univ., Cambridge, 1996).
26. Jha, P. Curbing the Epidemic: Governments and the Economics of Tobacco Control Ch. 1 (The World Bank, Washington, 1999).
27. National Cancer Institute. NCI Awards First Funding for Consortium of Cohorts Initiative [online], 〈http://www.nci.nih.gov/newscenter/ pressreleases/coho rtconsortium〉 (2003).
28. Grove, A. Only the Paranoid Survive: How to Exploit the Crisis Points That Challenge Every Company (Doubleday, New York, 1999)
29. Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998).
30. Caplen, N. J., Parrish, S., Imani, F., Fire, A. & Morgan, R. A. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl Acad. Sci. USA 98, 9742-9747 (2001).
31. Duxbury, M. S. & Whang, E. E. RNA interference: a practical approach. J. Sur. Res. 117, 339-344 (2004).
32. National Cancer Institute. The Nation's Investment in Cancer Research: a Plan and Budget Proposal for Fiscal Year 2005. NIH Publication No. 03-5446 [online], 〈http://cancer.gov/pdf/nci_2005_plan〉 (2003).
33. Jackson, E. L. et al. Analysis of lung tumor initiative and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).
34. Nagase, H., Mao, J. H., deKoning, J. P., Minami, T., & Balmain, A. Epistatic interactions between skin tumor modifier loci in interspecific (spretus/musculus) backcross mice. Cancer Res. 61, 1305-1308 (2001).
35. Rajasekhar, V. K. et al. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol. Cell. 12, 889-901 (2003).
36. Trotman, L. C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, 385-396 (2003).
37. Liu, P. T., Jenkins, N. A. & Copeland, N. G. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res. 13, 476-484 (2003).